PTWO vs. TOI, SHLT, FHLT, SHOT, TARA, BNGO, LTRN, VHAQ, TSBX, and PDEX
Should you be buying Pono Capital Two stock or one of its competitors? The main competitors of Pono Capital Two include Oncology Institute (TOI), SHL Telemedicine (SHLT), Future Health ESG (FHLT), Safety Shot (SHOT), Protara Therapeutics (TARA), Bionano Genomics (BNGO), Lantern Pharma (LTRN), Viveon Health Acquisition (VHAQ), Turnstone Biologics (TSBX), and Pro-Dex (PDEX). These companies are all part of the "medical" sector.
Oncology Institute (NASDAQ:TOI) and Pono Capital Two (NASDAQ:PTWO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.
Oncology Institute has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Pono Capital Two has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
Pono Capital Two has lower revenue, but higher earnings than Oncology Institute.
Pono Capital Two has a net margin of 0.00% compared to Pono Capital Two's net margin of -20.28%. Oncology Institute's return on equity of -6.63% beat Pono Capital Two's return on equity.
Oncology Institute presently has a consensus target price of $2.25, suggesting a potential upside of 261.45%. Given Pono Capital Two's higher probable upside, analysts plainly believe Oncology Institute is more favorable than Pono Capital Two.
Oncology Institute received 4 more outperform votes than Pono Capital Two when rated by MarketBeat users.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 60.8% of Pono Capital Two shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by company insiders. Comparatively, 63.9% of Pono Capital Two shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Oncology Institute had 12 more articles in the media than Pono Capital Two. MarketBeat recorded 16 mentions for Oncology Institute and 4 mentions for Pono Capital Two. Oncology Institute's average media sentiment score of 0.32 beat Pono Capital Two's score of -0.58 indicating that Pono Capital Two is being referred to more favorably in the news media.
Summary
Pono Capital Two beats Oncology Institute on 7 of the 13 factors compared between the two stocks.
Get Pono Capital Two News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTWO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTWO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pono Capital Two Competitors List
Related Companies and Tools
